Physician profile
Rick D Espe
NPI 1356411706
$3,058.93
in general payments reported to CMS, 2019-2025
27 companies · $557 in 2025
The $557 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $152 · 2021: $536 · 2022: $309 · 2023: $392 · 2024: $762 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $433.20 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $396.00 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $296.92 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $231.82 | 2019-2022 | |
| Cranial Technologies, INC | $205.87 | 2019-2025 | Doc Band |
| Sanofi Pasteur INC. | $170.65 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $154.25 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $146.38 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Pfizer INC. | $133.43 | 2019-2025 | |
| Adlon Therapeutics L.P. | $124.40 | 2020-2021 | |
| Kaleo, INC. | $117.89 | 2019-2023 | Auvi-Q |
| Tris Pharma INC | $113.71 | 2019-2025 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $91.90 | 2023-2025 | Bexsero, Penmenvy, Rotarix |
| Genentech USA, INC. | $81.68 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $62.86 | 2025 | Alvesco |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $59.50 | 2023-2024 | Xelstrym |
| Neos Therapeutics, Lp | $47.24 | 2019-2021 | |
| Shire North American Group INC | $26.99 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.38 | 2019 | |
| Verrica Pharmaceuticals INC. | $23.08 | 2025 | Ycanth |
| Sobi, INC | $18.35 | 2023 | |
| Organon LLC | $18.20 | 2025 | Nexplanon |
| Rhodes Pharmaceuticals L.P. | $17.43 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.55 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.35 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.25 | 2025 | Relexxii |
| Alexion Pharmaceuticals, INC. | $13.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rick Espe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.